- Home
- RPD vs MLTX Comparison
RPD vs MLTX Comparison
Compare RPD & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPD | MLTX |
|---|---|---|
| Founded | 2000 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 979.8M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPD | MLTX |
|---|---|---|
| Price | $12.65 | $16.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 21 | 9 |
| Target Price | ★ $22.40 | $22.22 |
| AVG Volume (30 Days) | 1.1M | ★ 3.5M |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $858,667,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.58 | N/A |
| P/E Ratio | $36.31 | ★ N/A |
| Revenue Growth | ★ 3.08 | N/A |
| 52 Week Low | $12.61 | $5.95 |
| 52 Week High | $40.25 | $62.75 |
Technical Indicators
Market Signals| Indicator | RPD | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.20 | 59.35 |
| Support Level | $13.22 | $15.70 |
| Resistance Level | $13.97 | $18.80 |
| Average True Range (ATR) | 0.53 | 1.20 |
| MACD | -0.18 | 0.44 |
| Stochastic Oscillator | 0.32 | 73.51 |
Price Performance
Historical ComparisonAbout RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.